AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00571961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir)
Description: 4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
Study NCT00571961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Buprenorphine will be obtained through prescription at the subject's drug treatment program.
Study NCT00571961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluations/Blood draws
Description: Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single-dose
Study NCT01537302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTO crossing in femoropopliteal arteries CONNECT II
Description: CTO crossing in femoropopliteal arteries using the Ocelot System
Study NCT01218880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 7.5mg
Description: M2ES Dosage：7.5mg/m2
Study NCT01218880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 15mg
Description: M2ES Dosage：15mg/m2
Study NCT01218880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 30mg
Description: M2ES Dosage：30mg/m2
Study NCT01218880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 45mg
Description: M2ES Dosage：45mg/m2
Study NCT03891121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Splint
Description: Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
Study NCT03891121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
Study NCT03086330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Study NCT03086330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Study NCT00335218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Climodien / Lafamme (BAY86-5027)
Description: 1 tablet daily (2 mg EV + 2 mg DNG)
Study NCT00335218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg
Study NCT01436370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
Study NCT01436370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
Study NCT02490046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Mannose
Description: Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
Study NCT04396197 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Description: Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
Study NCT04182100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Description: P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
Study NCT04182100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
Study NCT04182100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
Study NCT00685399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 subcutaneous dose
Study NCT00685399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 low dose (i.v)
Study NCT00685399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 high dose (i.v)
Study NCT00941993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis System (Acclarent)
Description: Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
Study NCT01825668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant Sterols
Study NCT01825668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High cholesterol
Study NCT01825668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03901196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elemental analysis
Description: LIBS multi elemental analysis of the specimen
Study NCT00617981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
Study NCT00617981 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 5% Dextrose Solution
Description: Single 30 minute intravenous infusion
Study NCT00948298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
Study NCT00948298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
Study NCT04154202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
Study NCT03470779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
Study NCT03470779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
Study NCT02006082 — intervention group
Intervention type: DEVICE
Intervention: Telemedicine video-consultation (TVC)
Description: All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
Study NCT02270151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyDiagnostick
Description: Diagnostick strategy with MyDiagnostick
Study NCT02726802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy vs. primary care interventions
Description: Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
Study NCT02726802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy vs. primary care interventions
Description: Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
Study NCT01595893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D 3
Description: 40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
Study NCT01595893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol 812 N
Description: Neutral oil of esters extracted from coconut and palm kernel
Study NCT00409682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
Study NCT00409682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
Study NCT00409682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
Study NCT00990717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-92 cells
Description: Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2
Study NCT00041782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Description: 200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
Study NCT00578955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin and 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study NCT00578955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Azithromycin
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study NCT00578955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study NCT02526043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic hepatectomy
Description: The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
Study NCT02526043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open hepatectomy
Description: The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
Study NCT04437238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KeepWell tool
Description: KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
Study NCT04437238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Usual care
Description: Participants allocated to the control condition will receive care as usual.
Study NCT01742364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioject ID Pen
Description: Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
Study NCT01742364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle and syringe
Description: Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
Study NCT01474213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: 1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
Study NCT01474213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil group
Description: target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
Study NCT02070068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT System
Study NCT02722512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Shock Protein Peptide Complex-96 (HSPPC-96)
Description: The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
Study NCT02722512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Clinically-indicated removal of the tumor
Study NCT02722512 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Focal Radiation Therapy
Study NCT03414801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Exposure
Description: Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
Study NCT05788757 — intervention group
Intervention type: DEVICE
Intervention: Optetrak Total Knee System
Description: Total Knee Arthroplasty using Exactech's Optetrak branded components.
Study NCT01732848 — intervention group
Intervention type: DRUG
Intervention: BMS-986094/INX-08189
Study NCT01732848 — intervention group
Intervention type: DRUG
Intervention: Placebo matching BMS-986094/INX-08189
Study NCT02456766 — intervention group
Intervention type: DEVICE
Intervention: FibroTouch
Study NCT02456766 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy
Study NCT02213562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200 mg of chrysanthemum flower oil
Study NCT02213562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of chrysanthemum flower oil
Study NCT02213562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg of chrysanthemum flower oil
Study NCT01451879 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Study NCT01451879 — intervention group
Intervention type: DRUG
Intervention: Miglustat
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Study NCT01919242 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
Study NCT03390699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbial profile
Description: microbiological testing
Study NCT01842048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Study NCT01842048 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External-beam radiotherapy
Study NCT01842048 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Study NCT03574064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-2 (GLP-2)
Description: Glucagon-Like Peptide-2 (GLP-2) injection.
Study NCT03574064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic polypeptide (GIP)
Description: Glucose-dependent insulinotropic polypeptide (GIP) injection.
Study NCT03574064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2+GIP
Description: GLP-2+GIP injection.
Study NCT03574064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection.
Study NCT02089490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVELIA® implantation
Description: Skin substitute implantation followed by ultra-thin epidermal graft
Study NCT01134653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump Stretch
Description: distraction with early mobilization
Study NCT01134653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jump Stretch
Description: distraction with early mobilization
Study NCT04025619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tape
Description: Sports tape
Study NCT01620177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol(oral) and placebo
Description: Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
Study NCT01620177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis(THC)(Inhaled) and Placebo
Description: Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
Study NCT01989507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Study NCT01989507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Study NCT01989507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral counseling for smoking cessation
Description: Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
Study NCT01989507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling for smoking cessation
Description: Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.